Johan Hansson

Publikationer
CV
Populärvetenskap och samverkan

Artiklar

Article: CANCERS. 2022;14(4):1040

Quality of Life in the First Year of Follow-Up in a Randomized Multicenter Trial Assessing the Role of Imaging after Radical Surgery of Stage IIB-C and III Cutaneous Melanoma (TRIM Study).

Naeser Y; Helgadottir H; Hansson J; Ingvar C; Elander NO; Flygare P; Nilsson C; Jakobsson F; Valachis A; Papantoniou D; Nordin Danfors A; Johansson H; Sundin A; Brandberg Y; Ullenhag GJ
Article: ACTA ONCOLOGICA. 2022;61(1):14-21

A biomarker panel predicts recurrence-free survival in ulcerated primary cutaneous melanoma.

Falkenius J; Keskitalo J; Kanter L; Johansson H; Höiom V; Hansson J; Egyhazi Brage S
Article: SCIENTIFIC REPORTS. 2021;11(1):11023

PTENP1-AS contributes to BRAF inhibitor resistance and is associated with adverse clinical outcome in stage III melanoma.

Vidarsdottir L; Azimi A; Das I; Sigvaldadottir I; Suryo Rahmanto A; Petri A; Kauppinen S; Ingvar C; Jönsson G; Olsson H; Frostvik Stolt M; Tuominen R; Sangfelt O; Pokrovskaja Tamm K; Hansson J; Grandér D; Egyházi Brage S; Johnsson P
Article: JOURNAL FOR IMMUNOTHERAPY OF CANCER. 2021;9(5):e002171

Predicting anti-PD-1 responders in malignant melanoma from the frequency of S100A9+ monocytes in the blood.

Rad Pour S; Pico de Coaña Y; Demorentin XM; Melief J; Thimma M; Wolodarski M; Gomez-Cabrero D; Hansson J; Kiessling R; Tegner J
Article: BMC PUBLIC HEALTH. 2021;21(1):692

Birth cohort-specific trends of sun-related behaviors among individuals from an international consortium of melanoma-prone families.

Lacson JCA; Zamani SA; Froes LAR; Mitra N; Qian L; Doyle SH; Azizi E; Balestrini C; Bishop DT; Bruno W; Carlos-Ortega B; Cuellar F; Cust AE; Elder DE; Gerdes A-M; Ghiorzo P; Grazziotin TC; Gruis NA; Hansson J; Hočevar M; Höiom V; Holland EA; Ingvar C; Landman G; Larre-Borges A; Mann GJ; Molgo M; Moredo LF; Olsson H; Out-Luiting JJ; Perić B; Pjanova D; Puig S; Salas-Alanis J; Schmid H; Wadt KAW; Newton-Bishop JA; Kanetsky PA; GenoMEL Study Group
Article: BMC CANCER. 2020;20(1):1197

TRIM study protocol - a prospective randomized multicenter Trial to assess the Role of Imaging during follow-up after radical surgery of stage IIB-C and III cutaneous malignant Melanoma.

Naeser Y; Helgadottir H; Brandberg Y; Hansson J; Bagge RO; Elander NO; Ingvar C; Isaksson K; Flygare P; Nilsson C; Jakobsson F; Del Val Munoz O; Valachis A; Jansson M; Sparring C; Ohlsson L; Dyrke U; Papantoniou D; Sundin A; Ullenhag GJ
Article: CELL DEATH & DISEASE. 2020;11(10):882

Inhibiting insulin and mTOR signaling by afatinib and crizotinib combination fosters broad cytotoxic effects in cutaneous malignant melanoma.

Das I; Chen H; Maddalo G; Tuominen R; Rebecca VW; Herlyn M; Hansson J; Davies MA; Egyházi Brage S
Article: MELANOMA RESEARCH. 2020;30(5):443-454

Silencing of CEBPB-AS1 modulates CEBPB expression and resensitizes BRAF-inhibitor resistant melanoma cells to vemurafenib.

Vidarsdottir L; Fernandes RV; Zachariadis V; Das I; Edsbäcker E; Sigvaldadottir I; Azimi A; Höiom V; Hansson J; Grandér D; Egyházi Brage S; Pokrovskaja Tamm K
Article: ONCOIMMUNOLOGY. 2020;9(1):1786888

PD-1 checkpoint blockade in advanced melanoma patients: NK cells, monocytic subsets and host PD-L1 expression as predictive biomarker candidates.

Pico de Coaña Y; Wolodarski M; van der Haar Àvila I; Nakajima T; Rentouli S; Lundqvist A; Masucci G; Hansson J; Kiessling R
Article: ONCOIMMUNOLOGY. 2020;9(1):1792058

Complete and long-lasting clinical responses in immune checkpoint inhibitor-resistant, metastasized melanoma treated with adoptive T cell transfer combined with DC vaccination.

Lövgren T; Wolodarski M; Wickström S; Edbäck U; Wallin M; Martell E; Markland K; Blomberg P; Nyström M; Lundqvist A; Jacobsson H; Ullenhag G; Ljungman P; Hansson J; Masucci G; Tell R; Poschke I; Adamson L; Mattsson J; Kiessling R
Article: CELL DEATH AND DIFFERENTIATION. 2020;27(7):2081-2098

AXL and CAV-1 play a role for MTH1 inhibitor TH1579 sensitivity in cutaneous malignant melanoma.

Das I; Gad H; Bräutigam L; Pudelko L; Tuominen R; Höiom V; Almlöf I; Rajagopal V; Hansson J; Helleday T; Egyházi Brage S; Warpman Berglund U
Article: NATURE GENETICS. 2020;52(5):494-504

Genome-wide association meta-analyses combining multiple risk phenotypes provide insights into the genetic architecture of cutaneous melanoma susceptibility.

Landi MT; Bishop DT; MacGregor S; Machiela MJ; Stratigos AJ; Ghiorzo P; Brossard M; Calista D; Choi J; Fargnoli MC; Zhang T; Rodolfo M; Trower AJ; Menin C; Martinez J; Hadjisavvas A; Song L; Stefanaki I; Scolyer R; Yang R; Goldstein AM; Potrony M; Kypreou KP; Pastorino L; Queirolo P; Pellegrini C; Cattaneo L; Zawistowski M; Gimenez-Xavier P; Rodriguez A; Elefanti L; Manoukian S; Rivoltini L; Smith BH; Loizidou MA; Del Regno L; Massi D; Mandala M; Khosrotehrani K; Akslen LA; Amos CI; Andresen PA; Avril M-F; Azizi E; Soyer HP; Bataille V; Dalmasso B; Bowdler LM; Burdon KP; Chen WV; Codd V; Craig JE; Dębniak T; Falchi M; Fang S; Friedman E; Simi S; Galan P; Garcia-Casado Z; Gillanders EM; Gordon S; Green A; Gruis NA; Hansson J; Harland M; Harris J; Helsing P; Henders A; Hočevar M; Höiom V; Hunter D; Ingvar C; Kumar R; Lang J; Lathrop GM; Lee JE; Li X; Lubiński J; Mackie RM; Malt M; Malvehy J; McAloney K; Mohamdi H; Molven A; Moses EK; Neale RE; Novaković S; Nyholt DR; Olsson H; Orr N; Fritsche LG; Puig-Butille JA; Qureshi AA; Radford-Smith GL; Randerson-Moor J; Requena C; Rowe C; Samani NJ; Sanna M; Schadendorf D; Schulze H-J; Simms LA; Smithers M; Song F; Swerdlow AJ; van der Stoep N; Kukutsch NA; Visconti A; Wallace L; Ward SV; Wheeler L; Sturm RA; Hutchinson A; Jones K; Malasky M; Vogt A; Zhou W; Pooley KA; Elder DE; Han J; Hicks B; Hayward NK; Kanetsky PA; Brummett C; Montgomery GW; Olsen CM; Hayward C; Dunning AM; Martin NG; Evangelou E; Mann GJ; Long G; Pharoah PDP; Easton DF; Barrett JH; Cust AE; Abecasis G; Duffy DL; Whiteman DC; Gogas H; De Nicolo A; Tucker MA; Newton-Bishop JA; GenoMEL Consortium; Q-MEGA and QTWIN Investigators; ATHENS Melanoma Study Group; 23andMe; SDH Study Group; IBD Investigators; Essen-Heidelberg Investigators; AMFS Investigators; MelaNostrum Consortium; Peris K; Chanock SJ; Demenais F; Brown KM; Puig S; Nagore E; Shi J; Iles MM; Law MH
Article: CANCER IMMUNOLOGY IMMUNOTHERAPY. 2020;69(4):513-522

High expression of ID1 in monocytes is strongly associated with phenotypic and functional MDSC markers in advanced melanoma.

Melief J; Pico de Coaña Y; Maas R; Fennemann F-L; Wolodarski M; Hansson J; Kiessling R
Article: ACTA NEUROPATHOLOGICA. 2020;139(2):347-364

Overlapping genetic architecture between Parkinson disease and melanoma.

Dube U; Ibanez L; Budde JP; Benitez BA; Davis AA; Harari O; Iles MM; Law MH; Brown KM; 23andMe Research Team; Melanoma-Meta-analysis Consortium; Cruchaga C
Article: FRONTIERS IN ONCOLOGY. 2020;10:51

Immunometabolic Network Interactions of the Kynurenine Pathway in Cutaneous Malignant Melanoma.

Rad Pour S; Morikawa H; Kiani NA; Gomez-Cabrero D; Hayes A; Zheng X; Pernemalm M; Lehtiö J; Mole DJ; Hansson J; Eriksson H; Tegnér J
Article: CELL DEATH & DISEASE. 2019;10(9):663

Combining ERBB family and MET inhibitors is an effective therapeutic strategy in cutaneous malignant melanoma independent of BRAF/NRAS mutation status.

Das I; Wilhelm M; Höiom V; Franco Marquez R; Costa Svedman F; Hansson J; Tuominen R; Egyhàzi Brage S
Article: SCIENTIFIC REPORTS. 2019;9(1):12150

Exhaustion of CD4+ T-cells mediated by the Kynurenine Pathway in Melanoma.

Rad Pour S; Morikawa H; Kiani NA; Yang M; Azimi A; Shafi G; Shang M; Baumgartner R; Ketelhuth DFJ; Kamleh MA; Wheelock CE; Lundqvist A; Hansson J; Tegnér J
Article: JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY. 2019;81(2):386-394

Estimating CDKN2A mutation carrier probability among global familial melanoma cases using GenoMELPREDICT.

Taylor NJ; Mitra N; Qian L; Avril M-F; Bishop DT; Bressac-de Paillerets B; Bruno W; Calista D; Cuellar F; Cust AE; Demenais F; Elder DE; Gerdes A-M; Ghiorzo P; Goldstein AM; Grazziotin TC; Gruis NA; Hansson J; Harland M; Hayward NK; Hocevar M; Höiom V; Holland EA; Ingvar C; Landi MT; Landman G; Larre-Borges A; Mann GJ; Nagore E; Olsson H; Palmer JM; Perić B; Pjanova D; Pritchard AL; Puig S; Schmid H; van der Stoep N; Tucker MA; Wadt KAW; Yang XR; Newton-Bishop JA; Kanetsky PA; GenoMEL Study Group
Article: LANCET ONCOLOGY. 2019;20(7):948-960

Identification of the optimal combination dosing schedule of neoadjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma (OpACIN-neo): a multicentre, phase 2, randomised, controlled trial.

Rozeman EA; Menzies AM; van Akkooi ACJ; Adhikari C; Bierman C; van de Wiel BA; Scolyer RA; Krijgsman O; Sikorska K; Eriksson H; Broeks A; van Thienen JV; Guminski AD; Acosta AT; Ter Meulen S; Koenen AM; Bosch LJW; Shannon K; Pronk LM; Gonzalez M; Ch'ng S; Grijpink-Ongering LG; Stretch J; Heijmink S; van Tinteren H; Haanen JBAG; Nieweg OE; Klop WMC; Zuur CL; Saw RPM; van Houdt WJ; Peeper DS; Spillane AJ; Hansson J; Schumacher TN; Long GV; Blank CU
Article: LANCET CHILD & ADOLESCENT HEALTH. 2019;3(5):332-342

MC1R variants in childhood and adolescent melanoma: a retrospective pooled analysis of a multicentre cohort.

Pellegrini C; Botta F; Massi D; Martorelli C; Facchetti F; Gandini S; Maisonneuve P; Avril M-F; Demenais F; Bressac-de Paillerets B; Hoiom V; Cust AE; Anton-Culver H; Gruber SB; Gallagher RP; Marrett L; Zanetti R; Dwyer T; Thomas NE; Begg CB; Berwick M; Puig S; Potrony M; Nagore E; Ghiorzo P; Menin C; Manganoni AM; Rodolfo M; Brugnara S; Passoni E; Sekulovic LK; Baldini F; Guida G; Stratigos A; Ozdemir F; Ayala F; Fernandez-de-Misa R; Quaglino P; Ribas G; Romanini A; Migliano E; Stanganelli I; Kanetsky PA; Pizzichetta MA; García-Borrón JC; Nan H; Landi MT; Little J; Newton-Bishop J; Sera F; Fargnoli MC; Raimondi S; IMI Study Group; GEM Study Group; M-SKIP Study Group
Article: FRONTIERS IN IMMUNOLOGY. 2019;10:2766

Cancer Neoepitopes for Immunotherapy: Discordance Between Tumor-Infiltrating T Cell Reactivity and Tumor MHC Peptidome Display.

Wickström SL; Lövgren T; Volkmar M; Reinhold B; Duke-Cohan JS; Hartmann L; Rebmann J; Mueller A; Melief J; Maas R; Ligtenberg M; Hansson J; Offringa R; Seliger B; Poschke I; Reinherz EL; Kiessling R
Article: EUROPEAN JOURNAL OF DERMATOLOGY. 2018;28(6):775-783

Assessment of quality of life using Skindex-16 in patients with advanced basal cell carcinoma treated with vismodegib in the STEVIE study.

Hansson J; Bartley K; Karagiannis T; Grob J-J; Kunstfeld R; Dréno B; Mortier L; Ascierto PA; Licitra L; Dutriaux C; Thomas L; Meyer N; Guillot B; Dummer R; Fife K; Ernst DS; Yim YM; Dimier N; Fittipaldo A; Basset-Séguin N; Hauschild A
Article: CANCER RESEARCH. 2018;78(20):5970-5979

Spatially Resolved Transcriptomics Enables Dissection of Genetic Heterogeneity in Stage III Cutaneous Malignant Melanoma.

Thrane K; Eriksson H; Maaskola J; Hansson J; Lundeberg J
Article: MELANOMA RESEARCH. 2018;28(4):333-340

The impact of patient characteristics and disease-specific factors on first-line treatment decisions for BRAF-mutated melanoma: results from a European expert panel study.

Ascierto PA; Bastholt L; Ferrucci PF; Hansson J; Márquez Rodas I; Payne M; Robert C; Thomas L; Utikal JS; Wolter P; Kudlac A; Tuson H; McKendrick J
Article: MOLECULAR SYSTEMS BIOLOGY. 2018;14(3):e7858

Targeting CDK2 overcomes melanoma resistance against BRAF and Hsp90 inhibitors.

Azimi A; Caramuta S; Seashore-Ludlow B; Boström J; Robinson JL; Edfors F; Tuominen R; Kemper K; Krijgsman O; Peeper DS; Nielsen J; Hansson J; Egyhazi Brage S; Altun M; Uhlen M; Maddalo G
Article: PLOS ONE. 2018;13(11):e0206942

Extracellular microvesicle microRNAs as predictive biomarkers for targeted therapy in metastastic cutaneous malignant melanoma.

Svedman FC; Lohcharoenkal W; Bottai M; Brage SE; Sonkoly E; Hansson J; Pivarcsi A; Eriksson H
Article: CELLULAR ONCOLOGY. 2017;40(6):631-638

ΔNp73 regulates the expression of the multidrug-resistance genes ABCB1 and ABCB5 in breast cancer and melanoma cells - a short report.

Sakil HAM; Stantic M; Wolfsberger J; Brage SE; Hansson J; Wilhelm MT
Article: JOURNAL OF INVESTIGATIVE DERMATOLOGY. 2017;137(12):2606-2612

Germline Variation at CDKN2A and Associations with Nevus Phenotypes among Members of Melanoma Families.

Taylor NJ; Mitra N; Goldstein AM; Tucker MA; Avril M-F; Azizi E; Bergman W; Bishop DT; Bressac-de Paillerets B; Bruno W; Calista D; Cannon-Albright LA; Cuellar F; Cust AE; Demenais F; Elder DE; Gerdes A-M; Ghiorzo P; Grazziotin TC; Hansson J; Harland M; Hayward NK; Hocevar M; Höiom V; Ingvar C; Landi MT; Landman G; Larre-Borges A; Leachman SA; Mann GJ; Nagore E; Olsson H; Palmer JM; Perić B; Pjanova D; Pritchard A; Puig S; van der Stoep N; Wadt KAW; Whitaker L; Yang XR; Newton Bishop JA; Gruis NA; Kanetsky PA; GenoMEL Study Group
Article: EUROPEAN JOURNAL OF CANCER. 2017;86:334-348

Vismodegib in patients with advanced basal cell carcinoma: Primary analysis of STEVIE, an international, open-label trial.

Basset-Séguin N; Hauschild A; Kunstfeld R; Grob J; Dréno B; Mortier L; Ascierto PA; Licitra L; Dutriaux C; Thomas L; Meyer N; Guillot B; Dummer R; Arenberger P; Fife K; Raimundo A; Dika E; Dimier N; Fittipaldo A; Xynos I; Hansson J
Article: JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY. 2017;77(5):893-901

Cancer risks and survival in patients with multiple primary melanomas: Association with family history of melanoma and germline CDKN2A mutation status.

Helgadottir H; Tuominen R; Olsson H; Hansson J; Höiom V
Article: INTERNATIONAL JOURNAL OF CANCER. 2017;141(7):1345-1354

Primary tumor sites in relation to ultraviolet radiation exposure and skin visibility correlate with survival in cutaneous melanoma.

Gordon D; Hansson J; Eloranta S; Gordon M; Gillgren P; Smedby KE
Article: CELL DEATH & DISEASE. 2017;8(8):e3029

Silencing FLI or targeting CD13/ANPEP lead to dephosphorylation of EPHA2, a mediator of BRAF inhibitor resistance, and induce growth arrest or apoptosis in melanoma cells.

Azimi A; Tuominen R; Costa Svedman F; Caramuta S; Pernemalm M; Frostvik Stolt M; Kanter L; Kharaziha P; Lehtiö J; Hertzman Johansson C; Höiom V; Hansson J; Egyhazi Brage S
Article: BMC CANCER. 2017;17(1):584

Presence of immune cells, low tumor proliferation and wild type BRAF mutation status is associated with a favourable clinical outcome in stage III cutaneous melanoma.

Falkenius J; Johansson H; Tuominen R; Frostvik Stolt M; Hansson J; Egyhazi Brage S
Article: ANNALS OF ONCOLOGY. 2017;28(7):1631-1639

Dabrafenib plus trametinib versus dabrafenib monotherapy in patients with metastatic BRAF V600E/K-mutant melanoma: long-term survival and safety analysis of a phase 3 study.

Long GV; Flaherty KT; Stroyakovskiy D; Gogas H; Levchenko E; de Braud F; Larkin J; Garbe C; Jouary T; Hauschild A; Chiarion-Sileni V; Lebbe C; Mandalà M; Millward M; Arance A; Bondarenko I; Haanen JBAG; Hansson J; Utikal J; Ferraresi V; Mohr P; Probachai V; Schadendorf D; Nathan P; Robert C; Ribas A; Davies MA; Lane SR; Legos JJ; Mookerjee B; Grob J-J
Article: ANALYTICAL AND BIOANALYTICAL CHEMISTRY. 2017;409(15):3749-3756

Simple and cost-effective liquid chromatography-mass spectrometry method to measure dabrafenib quantitatively and six metabolites semi-quantitatively in human plasma.

Vikingsson S; Dahlberg J-O; Hansson J; Höiom V; Gréen H
Article: LAKARTIDNINGEN. 2017;114:ELM9

[Great advances in the systemic treatment in malignant melanoma patients].

Ullenhag G; Hansson J; Ny L
Article: LAKARTIDNINGEN. 2017;114:ELAR

[Melanoma in places other than the skin: eye and mucous membrane melanomas].

All-Eriksson C; Seregard S; Hansson J
Article: EUROPEAN JOURNAL OF CANCER. 2017;75:313-322

More than 5000 patients with metastatic melanoma in Europe per year do not have access to recommended first-line innovative treatments.

Kandolf Sekulovic L; Peris K; Hauschild A; Stratigos A; Grob J-J; Nathan P; Dummer R; Forsea A-M; Hoeller C; Gogas H; Demidov L; Lebbe C; Blank C; Olah J; Bastholt L; Herceg D; Neyns B; Vieira R; Hansson J; Rutkowski P; Krajsova I; Bylaite-Bucinskiene M; Zalaudek I; Maric-Brozic J; Babovic N; Banjin M; Putnik K; Weinlich G; Todorovic V; Kirov K; Ocvirk J; Zhukavets A; Kukushkina M; De La Cruz Merino L; Ymeri A; Risteski M; Garbe C
Article: ONCOTARGET. 2017;8(13):21539-21553

Ipilimumab treatment decreases monocytic MDSCs and increases CD8 effector memory T cells in long-term survivors with advanced melanoma.

de Coaña YP; Wolodarski M; Poschke I; Yoshimoto Y; Yang Y; Nyström M; Edbäck U; Brage SE; Lundqvist A; Masucci GV; Hansson J; Kiessling R
Article: INTERNATIONAL JOURNAL OF CANCER. 2016;139(12):2722-2729

Epidemiology of cutaneous melanoma in Sweden-Stage-specific survival and rate of recurrence.

Rockberg J; Amelio JM; Taylor A; Jörgensen L; Ragnhammar P; Hansson J
Article: HUMAN GENETICS. 2016;135(11):1241-1249

Multiple rare variants in high-risk pancreatic cancer-related genes may increase risk for pancreatic cancer in a subset of patients with and without germline CDKN2A mutations.

Yang XR; Rotunno M; Xiao Y; Ingvar C; Helgadottir H; Pastorino L; van Doorn R; Bennett H; Graham C; Sampson JN; Malasky M; Vogt A; Zhu B; Bianchi-Scarra G; Bruno W; Queirolo P; Fornarini G; Hansson J; Tuominen R; Burdett L; Hicks B; Hutchinson A; Jones K; Yeager M; Chanock SJ; Landi MT; Höiom V; Olsson H; Gruis N; Ghiorzo P; Tucker MA; Goldstein AM
Article: JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE. 2016;108(11):djw135

Germline CDKN2A Mutation Status and Survival in Familial Melanoma Cases.

Helgadottir H; Höiom V; Tuominen R; Nielsen K; Jönsson G; Olsson H; Hansson J
Article: BIOMEDICAL CHROMATOGRAPHY. 2016;30(8):1234-1239

Novel rapid liquid chromatography tandem masspectrometry method for vemurafenib and metabolites in human plasma, including metabolite concentrations at steady state.

Vikingsson S; Strömqvist M; Svedberg A; Hansson J; Höiom V; Gréen H
Article: MELANOMA RESEARCH. 2016;26(4):367-376

Prognostic and predictive value of YKL-40 in stage IIB-III melanoma.

Krogh M; Christensen I; Bouwhuis M; Johansen JS; Nørgaard P; Schmidt H; Hansson J; Suciu S; Eggermont AMM; Bastholt L; Nordic Melanoma Group and EORTC Melanoma Group
Article: INTERNATIONAL JOURNAL OF CANCER. 2016;139(3):543-553

Prognostic factors and disease-specific survival among immigrants diagnosed with cutaneous malignant melanoma in Sweden.

Simberg-Danell C; Lyth J; Månsson-Brahme E; Frohm-Nilsson M; Carstensen J; Hansson J; Eriksson H
Article: GENES CHROMOSOMES & CANCER. 2016;55(7):601-611

The role of germline alterations in the DNA damage response genes BRIP1 and BRCA2 in melanoma susceptibility.

Tuominen R; Engström PG; Helgadottir H; Eriksson H; Unneberg P; Kjellqvist S; Yang M; Lindén D; Edsgärd D; Hansson J; Höiom V
Article: INTERNATIONAL JOURNAL OF CANCER. 2015;137(9):2220-2226

CDKN2a mutation-negative melanoma families have increased risk exclusively for skin cancers but not for other malignancies.

Helgadottir H; Höiom V; Tuominen R; Jönsson G; Månsson-Brahme E; Olsson H; Hansson J
Article: NATURE GENETICS. 2015;47(9):987-995

Genome-wide meta-analysis identifies five new susceptibility loci for cutaneous malignant melanoma.

Law MH; Bishop DT; Lee JE; Brossard M; Martin NG; Moses EK; Song F; Barrett JH; Kumar R; Easton DF; Pharoah PDP; Swerdlow AJ; Kypreou KP; Taylor JC; Harland M; Randerson-Moor J; Akslen LA; Andresen PA; Avril M-F; Azizi E; Scarrà GB; Brown KM; Dębniak T; Duffy DL; Elder DE; Fang S; Friedman E; Galan P; Ghiorzo P; Gillanders EM; Goldstein AM; Gruis NA; Hansson J; Helsing P; Hočevar M; Höiom V; Ingvar C; Kanetsky PA; Chen WV; GenoMEL Consortium; Essen-Heidelberg Investigators; SDH Study Group; Q-MEGA and QTWIN Investigators; AMFS Investigators; ATHENS Melanoma Study Group; Landi MT; Lang J; Lathrop GM; Lubiński J; Mackie RM; Mann GJ; Molven A; Montgomery GW; Novaković S; Olsson H; Puig S; Puig-Butille JA; Qureshi AA; Radford-Smith GL; van der Stoep N; van Doorn R; Whiteman DC; Craig JE; Schadendorf D; Simms LA; Burdon KP; Nyholt DR; Pooley KA; Orr N; Stratigos AJ; Cust AE; Ward SV; Hayward NK; Han J; Schulze H-J; Dunning AM; Bishop JAN; Demenais F; Amos CI; MacGregor S; Iles MM
Article: MELANOMA RESEARCH. 2015;25(4):348-356

Time trends in incidence of cutaneous melanoma by detailed anatomical location and patterns of ultraviolet radiation exposure: a retrospective population-based study.

Gordon D; Gillgren P; Eloranta S; Olsson H; Gordon M; Hansson J; Smedby KE
Article: LANCET. 2015;386(9992):444-451

Dabrafenib and trametinib versus dabrafenib and placebo for Val600 BRAF-mutant melanoma: a multicentre, double-blind, phase 3 randomised controlled trial.

Long GV; Stroyakovskiy D; Gogas H; Levchenko E; de Braud F; Larkin J; Garbe C; Jouary T; Hauschild A; Grob J-J; Chiarion-Sileni V; Lebbe C; Mandalà M; Millward M; Arance A; Bondarenko I; Haanen JBAG; Hansson J; Utikal J; Ferraresi V; Kovalenko N; Mohr P; Probachai V; Schadendorf D; Nathan P; Robert C; Ribas A; DeMarini DJ; Irani JG; Swann S; Legos JJ; Jin F; Mookerjee B; Flaherty K
Article: INTERNATIONAL JOURNAL OF CANCER. 2015;136(12):2844-2853

MGMT promoter methylation is associated with temozolomide response and prolonged progression-free survival in disseminated cutaneous melanoma.

Tuominen R; Jewell R; van den Oord JJ; Wolter P; Stierner U; Lindholm C; Hertzman Johansson C; Lindén D; Johansson H; Frostvik Stolt M; Walker C; Snowden H; Newton-Bishop J; Hansson J; Egyházi Brage S
Article: ONCOTARGET. 2015;6(16):14139-14152

A simplified interventional mapping system (SIMS) for the selection of combinations of targeted treatments in non-small cell lung cancer.

Lazar V; Rubin E; Depil S; Pawitan Y; Martini J-F; Gomez-Navarro J; Yver A; Kan Z; Dry JR; Kehren J; Validire P; Rodon J; Vielh P; Ducreux M; Galbraith S; Lehnert M; Onn A; Berger R; Pierotti MA; Porgador A; Pramesh CS; Ye D-W; Carvalho AL; Batist G; Le Chevalier T; Morice P; Besse B; Vassal G; Mortlock A; Hansson J; Berindan-Neagoe I; Dann R; Haspel J; Irimie A; Laderman S; Nechushtan H; Al Omari AS; Haywood T; Bresson C; Soo KC; Osman I; Mata H; Lee JJ; Jhaveri K; Meurice G; Palmer G; Lacroix L; Koscielny S; Eterovic KA; Blay J-Y; Buller R; Eggermont A; Schilsky RL; Mendelsohn J; Soria J-C; Rothenberg M; Scoazec J-Y; Hong WK; Kurzrock R
Article: JAMA SURGERY. 2015;150(6):512-518

Short-term Results of a Magnetic Resonance Imaging-Based Swedish Screening Program for Individuals at Risk for Pancreatic Cancer.

Del Chiaro M; Verbeke CS; Kartalis N; Pozzi Mucelli R; Gustafsson P; Hansson J; Haas SL; Segersvärd R; Andren-Sandberg Å; Löhr J-M
Article: CANCER IMMUNOLOGY IMMUNOTHERAPY. 2015;64(6):769-776

Evaluation of serum osteopontin level and gene polymorphism as biomarkers: analyses from the Nordic Adjuvant Interferon alpha Melanoma trial.

Prasmickaite L; Berge G; Bettum IJ; Aamdal S; Hansson J; Bastholt L; Øijordsbakken M; Boye K; Mælandsmo GM
Article: MELANOMA RESEARCH. 2015;25(3):185-188

TERT promoter mutations in sinonasal malignant melanoma: a study of 49 cases.

Jangard M; Zebary A; Ragnarsson-Olding B; Hansson J
Article: LANCET ONCOLOGY. 2015;16(6):729-736

Vismodegib in patients with advanced basal cell carcinoma (STEVIE): a pre-planned interim analysis of an international, open-label trial.

Basset-Seguin N; Hauschild A; Grob J-J; Kunstfeld R; Dréno B; Mortier L; Ascierto PA; Licitra L; Dutriaux C; Thomas L; Jouary T; Meyer N; Guillot B; Dummer R; Fife K; Ernst DS; Williams S; Fittipaldo A; Xynos I; Hansson J
Article: CANCER RESEARCH. 2015;75(7):1187-1190

VEGF-A Expression Correlates with TP53 Mutations in Non-Small Cell Lung Cancer: Implications for Antiangiogenesis Therapy.

Schwaederlé M; Lazar V; Validire P; Hansson J; Lacroix L; Soria J-C; Pawitan Y; Kurzrock R
Article: JAMA DERMATOLOGY. 2015;151(4):410-416

BRAFV600E protein expression in primary cutaneous malignant melanomas and paired metastases.

Eriksson H; Zebary A; Vassilaki I; Omholt K; Ghaderi M; Hansson J
Article: INTERNATIONAL JOURNAL OF CANCER. 2015;136(6):1351-1360

Fine mapping of genetic susceptibility loci for melanoma reveals a mixture of single variant and multiple variant regions.

Barrett JH; Taylor JC; Bright C; Harland M; Dunning AM; Akslen LA; Andresen PA; Avril M-F; Azizi E; Bianchi Scarrà G; Brossard M; Brown KM; Dębniak T; Elder DE; Friedman E; Ghiorzo P; Gillanders EM; Gruis NA; Hansson J; Helsing P; Hočevar M; Höiom V; Ingvar C; Landi MT; Lang J; Lathrop GM; Lubiński J; Mackie RM; Molven A; Novaković S; Olsson H; Puig S; Puig-Butille JA; van der Stoep N; van Doorn R; van Workum W; Goldstein AM; Kanetsky PA; Pharoah PDP; Demenais F; Hayward NK; Newton Bishop JA; Bishop DT; Iles MM; GenoMEL Consortium
Article: BRITISH JOURNAL OF DERMATOLOGY. 2015;172(3):700-706

Trends in cutaneous malignant melanoma in Sweden 1997-2011: thinner tumours and improved survival among men.

Lyth J; Eriksson H; Hansson J; Ingvar C; Jansson M; Lapins J; Månsson-Brahme E; Naredi P; Stierner U; Ullenhag G; Carstensen J; Lindholm C
Article: CANCER IMMUNOLOGY IMMUNOTHERAPY. 2015;64(2):173-180

Benefit of adjuvant interferon alfa-2b (IFN-α) therapy in melanoma patients with high serum MMP-8 levels.

Vihinen P; Tervahartiala T; Sorsa T; Hansson J; Bastholt L; Aamdal S; Stierner U; Pyrhönen S; Syrjänen K; Lundin J; Hernberg M
Article: INTERNATIONAL JOURNAL OF CANCER. 2015;136(3):618-631

MC1R variants increased the risk of sporadic cutaneous melanoma in darker-pigmented Caucasians: a pooled-analysis from the M-SKIP project.

Pasquali E; García-Borrón JC; Fargnoli MC; Gandini S; Maisonneuve P; Bagnardi V; Specchia C; Liu F; Kayser M; Nijsten T; Nagore E; Kumar R; Hansson J; Kanetsky PA; Ghiorzo P; Debniak T; Branicki W; Gruis NA; Han J; Dwyer T; Blizzard L; Landi MT; Palmieri G; Ribas G; Stratigos A; Council ML; Autier P; Little J; Newton-Bishop J; Sera F; Raimondi S; M-SKIP Study Group
Article: BRITISH JOURNAL OF DERMATOLOGY. 2015;172(1):175-186

Prognostic factors in localized invasive primary cutaneous malignant melanoma: results of a large population-based study.

Eriksson H; Frohm-Nilsson M; Järås J; Kanter-Lewensohn L; Kjellman P; Månsson-Brahme E; Vassilaki I; Hansson J
Article: NEW ENGLAND JOURNAL OF MEDICINE. 2014;371(20):1877-1888

Combined BRAF and MEK inhibition versus BRAF inhibition alone in melanoma.

Long GV; Stroyakovskiy D; Gogas H; Levchenko E; de Braud F; Larkin J; Garbe C; Jouary T; Hauschild A; Grob JJ; Chiarion Sileni V; Lebbe C; Mandalà M; Millward M; Arance A; Bondarenko I; Haanen JBAG; Hansson J; Utikal J; Ferraresi V; Kovalenko N; Mohr P; Probachai V; Schadendorf D; Nathan P; Robert C; Ribas A; DeMarini DJ; Irani JG; Casey M; Ouellet D; Martin A-M; Le N; Patel K; Flaherty K
Article: INTERNATIONAL JOURNAL OF CANCER. 2014;135(7):1625-1633

Inherited variation in the PARP1 gene and survival from melanoma.

Davies JR; Jewell R; Affleck P; Anic GM; Randerson-Moor J; Ozola A; Egan KM; Elliott F; García-Casado Z; Hansson J; Harland M; Höiom V; Jian G; Jönsson G; Kumar R; Nagore E; Wendt J; Olsson H; Park JY; Patel P; Pjanova D; Puig S; Schadendorf D; Sivaramakrishna Rachakonda P; Snowden H; Stratigos AJ; Bafaloukos D; Ogbah Z; Sucker A; Van den Oord JJ; Van Doorn R; Walker C; Okamoto I; Wolter P; Barrett JH; Timothy Bishop D; Newton-Bishop J
Article: CANCER IMMUNOLOGY IMMUNOTHERAPY. 2014;63(10):1061-1071

A phase I clinical trial combining dendritic cell vaccination with adoptive T cell transfer in patients with stage IV melanoma.

Poschke I; Lövgren T; Adamson L; Nyström M; Andersson E; Hansson J; Tell R; Masucci GV; Kiessling R
Article: ANNALS OF SURGICAL ONCOLOGY. 2014;21(11):3386-3394

Sentinel node location in trunk and extremity melanomas: uncommon or multiple lymph drainage does not affect survival.

Gordon D; Smedby KE; Schultz I; Olsson H; Ingvar C; Hansson J; Gillgren P
Article: JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE. 2014;106(10):dju267

The effect on melanoma risk of genes previously associated with telomere length.

Iles MM; Bishop DT; Taylor JC; Hayward NK; Brossard M; Cust AE; Dunning AM; Lee JE; Moses EK; Akslen LA; AMFS Investigators; Andresen PA; Avril M-F; Azizi E; Scarrà GB; Brown KM; Dębniak T; Elder DE; Friedman E; Ghiorzo P; Gillanders EM; Goldstein AM; Gruis NA; Hansson J; Harland M; Helsing P; Hočevar M; Höiom V; IBD investigators; Ingvar C; Kanetsky PA; Landi MT; Lang J; Lathrop GM; Lubiński J; Mackie RM; Martin NG; Molven A; Montgomery GW; Novaković S; Olsson H; Puig S; Puig-Butille JA; QMEGA and QTWIN Investigators; Radford-Smith GL; Randerson-Moor J; SDH Study Group; van der Stoep N; van Doorn R; Whiteman DC; MacGregor S; Pooley KA; Ward SV; Mann GJ; Amos CI; Pharoah PDP; Demenais F; Law MH; Newton Bishop JA; Barrett JH; GenoMEL Consortium
Article: MATRIX BIOLOGY. 2014;38:69-83

Laminins 411 and 421 differentially promote tumor cell migration via α6β1 integrin and MCAM (CD146).

Ishikawa T; Wondimu Z; Oikawa Y; Gentilcore G; Kiessling R; Egyhazi Brage S; Hansson J; Patarroyo M
Article: TRIALS. 2014;15:317

Isolated hepatic perfusion as a treatment for uveal melanoma liver metastases (the SCANDIUM trial): study protocol for a randomized controlled trial.

Olofsson R; Ny L; Eilard MS; Rizell M; Cahlin C; Stierner U; Lönn U; Hansson J; Ljuslinder I; Lundgren L; Ullenhag G; Kiilgaard JF; Nilsson J; Lindnér P
Article: JOURNAL OF MEDICAL GENETICS. 2014;51(8):545-552

High risk of tobacco-related cancers in CDKN2A mutation-positive melanoma families.

Helgadottir H; Höiom V; Jönsson G; Tuominen R; Ingvar C; Borg A; Olsson H; Hansson J
Article: JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY. 2014;71(2):245-248

Risk of cutaneous malignant melanoma in patients with celiac disease: a population-based study.

Lebwohl B; Eriksson H; Hansson J; Green PHR; Ludvigsson JF
Article: BRITISH JOURNAL OF CANCER. 2014;110(10):2489-2495

Proteomics analysis of melanoma metastases: association between S100A13 expression and chemotherapy resistance.

Azimi A; Pernemalm M; Frostvik Stolt M; Hansson J; Lehtiö J; Egyházi Brage S; Hertzman Johansson C
Article: JOURNAL OF CLINICAL ONCOLOGY. 2014;32(13):1356-1364

Later stage at diagnosis and worse survival in cutaneous malignant melanoma among men living alone: a nationwide population-based study from Sweden.

Eriksson H; Lyth J; Månsson-Brahme E; Frohm-Nilsson M; Ingvar C; Lindholm C; Naredi P; Stierner U; Carstensen J; Hansson J
Article: CANCER GENETICS. 2014;207(3):70-74

Investigation of a putative melanoma susceptibility locus at chromosome 3q29.

Tuominen R; Jönsson G; Enerbäck C; Appelqvist F; Olsson H; Ingvar C; Hansson J; Höiom V
Article: PIGMENT CELL & MELANOMA RESEARCH. 2014;27(2):234-243

An inherited variant in the gene coding for vitamin D-binding protein and survival from cutaneous melanoma: a BioGenoMEL study.

Davies JR; Field S; Randerson-Moor J; Harland M; Kumar R; Anic GM; Nagore E; Hansson J; Höiom V; Jönsson G; Gruis NA; Park JY; Guan J; Sivaramakrishna Rachakonda P; Wendt J; Pjanova D; Puig S; Schadendorf D; Okamoto I; Olsson H; Affleck P; García-Casado Z; Puig-Butille JA; Stratigos AJ; Kodela E; Donina S; Sucker A; Hosen I; Egan KM; Barrett JH; van Doorn R; Bishop DT; Newton-Bishop J
Article: CANCER EPIDEMIOLOGY. 2014;38(1):93-99

Estimating the cure proportion of malignant melanoma, an alternative approach to assess long term survival: a population-based study.

Andersson TM-L; Eriksson H; Hansson J; Månsson-Brahme E; Dickman PW; Eloranta S; Lambe M; Lambert PC
Article: BMC MEDICAL GENOMICS. 2013;6:53

Integrated molecular portrait of non-small cell lung cancers.

Lazar V; Suo C; Orear C; van den Oord J; Balogh Z; Guegan J; Job B; Meurice G; Ripoche H; Calza S; Hasmats J; Lundeberg J; Lacroix L; Vielh P; Dufour F; Lehtiö J; Napieralski R; Eggermont A; Schmitt M; Cadranel J; Besse B; Girard P; Blackhall F; Validire P; Soria J-C; Dessen P; Hansson J; Pawitan Y
Article: MELANOMA RESEARCH. 2013;23(6):452-460

High expression of glycolytic and pigment proteins is associated with worse clinical outcome in stage III melanoma.

Falkenius J; Lundeberg J; Johansson H; Tuominen R; Frostvik-Stolt M; Hansson J; Egyhazi Brage S
Article: JOURNAL OF DERMATOLOGICAL SCIENCE. 2013;72(3):284-289

KIT, NRAS, BRAF and PTEN mutations in a sample of Swedish patients with acral lentiginous melanoma.

Zebary A; Omholt K; Vassilaki I; Höiom V; Lindén D; Viberg L; Kanter-Lewensohn L; Johansson CH; Hansson J
Article: MELANOMA RESEARCH. 2013;23(5):360-365

Association of MITF and other melanosome-related proteins with chemoresistance in melanoma tumors and cell lines.

Hertzman Johansson C; Azimi A; Frostvik Stolt M; Shojaee S; Wiberg H; Grafström E; Hansson J; Egyházi Brage S
Article: CANCER IMMUNOLOGY RESEARCH. 2013;1(3):158-162

Ipilimumab treatment results in an early decrease in the frequency of circulating granulocytic myeloid-derived suppressor cells as well as their Arginase1 production.

Pico de Coaña Y; Poschke I; Gentilcore G; Mao Y; Nyström M; Hansson J; Masucci GV; Kiessling R
Article: BRITISH JOURNAL OF CANCER. 2013;109(3):559-564

KIT, NRAS and BRAF mutations in sinonasal mucosal melanoma: a study of 56 cases.

Zebary A; Jangard M; Omholt K; Ragnarsson-Olding B; Hansson J
Article: ACTA ONCOLOGICA. 2013;52(6):1086-1093

Role functioning before start of adjuvant treatment was an independent prognostic factor for survival and time to failure. A report from the Nordic adjuvant interferon trial for patients with high-risk melanoma.

Brandberg Y; Johansson H; Aamdal S; Bastholt L; Hernberg M; Stierner U; von der Maase H; Hansson J; Nordic Melanoma Cooperative Group
Article: EUROPEAN JOURNAL OF CANCER. 2013;49(12):2705-2716

Low level of education is associated with later stage at diagnosis and reduced survival in cutaneous malignant melanoma: a nationwide population-based study in Sweden.

Eriksson H; Lyth J; Månsson-Brahme E; Frohm-Nilsson M; Ingvar C; Lindholm C; Naredi P; Stierner U; Wagenius G; Carstensen J; Hansson J
Article: ACTA DERMATO-VENEREOLOGICA. 2013;93(4):411-416

Interobserver variability of histopathological prognostic parameters in cutaneous malignant melanoma: impact on patient management.

Eriksson H; Frohm-Nilsson M; Hedblad M-A; Hellborg H; Kanter-Lewensohn L; Krawiec K; Lundh Rozell B; Månsson-Brahme E; Hansson J
Article: CANCER RESEARCH. 2013;73(13):3877-3887

Melanoma-educated CD14+ cells acquire a myeloid-derived suppressor cell phenotype through COX-2-dependent mechanisms.

Mao Y; Poschke I; Wennerberg E; Pico de Coaña Y; Egyhazi Brage S; Schultz I; Hansson J; Masucci G; Lundqvist A; Kiessling R
Article: GENES CHROMOSOMES & CANCER. 2013;52(4):378-384

Hereditary uveal melanoma: a report of a germline mutation in BAP1.

Höiom V; Edsgärd D; Helgadottir H; Eriksson H; All-Ericsson C; Tuominen R; Ivanova I; Lundeberg J; Emanuelsson O; Hansson J
Article: NATURE GENETICS. 2013;45(4):428-432

A variant in FTO shows association with melanoma risk not due to BMI.

Iles MM; Law MH; Stacey SN; Han J; Fang S; Pfeiffer R; Harland M; Macgregor S; Taylor JC; Aben KK; Akslen LA; Avril M-F; Azizi E; Bakker B; Benediktsdottir KR; Bergman W; Scarrà GB; Brown KM; Calista D; Chaudru V; Fargnoli MC; Cust AE; Demenais F; de Waal AC; Dębniak T; Elder DE; Friedman E; Galan P; Ghiorzo P; Gillanders EM; Goldstein AM; Gruis NA; Hansson J; Helsing P; Hočevar M; Höiom V; Hopper JL; Ingvar C; Janssen M; Jenkins MA; Kanetsky PA; Kiemeney LA; Lang J; Lathrop GM; Leachman S; Lee JE; Lubiński J; Mackie RM; Mann GJ; Martin NG; Mayordomo JI; Molven A; Mulder S; Nagore E; Novaković S; Okamoto I; Olafsson JH; Olsson H; Pehamberger H; Peris K; Grasa MP; Planelles D; Puig S; Puig-Butille JA; Randerson-Moor J; Requena C; Rivoltini L; Rodolfo M; Santinami M; Sigurgeirsson B; Snowden H; Song F; Sulem P; Thorisdottir K; Tuominen R; Van Belle P; van der Stoep N; van Rossum MM; Wei Q; Wendt J; Zelenika D; Zhang M; Landi MT; Thorleifsson G; Bishop DT; Amos CI; Hayward NK; Stefansson K; Bishop JAN; Barrett JH; GenoMEL Consortium; Q-MEGA and AMFS Investigators
Article: BRITISH JOURNAL OF DERMATOLOGY. 2013;168(4):779-786

Prognostic subclassifications of T1 cutaneous melanomas based on ulceration, tumour thickness and Clark's level of invasion: results of a population-based study from the Swedish Melanoma Register.

Lyth J; Hansson J; Ingvar C; Månsson-Brahme E; Naredi P; Stierner U; Wagenius G; Lindholm C; Swedish Melanoma Study Group
Article: RHINOLOGY. 2013;51(1):22-30

Primary sinonasal malignant melanoma: a nationwide study of the Swedish population, 1960-2000.

Jangard M; Hansson J; Ragnarsson-Olding B
Article: EUROPEAN JOURNAL OF CANCER. 2012;48(13):2012-2019

Health-related quality of life in patients with high-risk melanoma randomised in the Nordic phase 3 trial with adjuvant intermediate-dose interferon alfa-2b.

Brandberg Y; Aamdal S; Bastholt L; Hernberg M; Stierner U; von der Maase H; Hansson J
Article: BMC MEDICAL RESEARCH METHODOLOGY. 2012;12:116

Melanocortin-1 receptor, skin cancer and phenotypic characteristics (M-SKIP) project: study design and methods for pooling results of genetic epidemiological studies.

Raimondi S; Gandini S; Fargnoli MC; Bagnardi V; Maisonneuve P; Specchia C; Kumar R; Nagore E; Han J; Hansson J; Kanetsky PA; Ghiorzo P; Gruis NA; Dwyer T; Blizzard L; Fernandez-de-Misa R; Branicki W; Debniak T; Morling N; Landi MT; Palmieri G; Ribas G; Stratigos A; Cornelius L; Motokawa T; Anno S; Helsing P; Wong TH; Autier P; García-Borrón JC; Little J; Newton-Bishop J; Sera F; Liu F; Kayser M; Nijsten T; GEM Study Group; M-SKIP Study Group
Article: PIGMENT CELL & MELANOMA RESEARCH. 2012;25(3):384-394

Inherited variants in the MC1R gene and survival from cutaneous melanoma: a BioGenoMEL study.

Davies JR; Randerson-Moor J; Kukalizch K; Harland M; Kumar R; Madhusudan S; Nagore E; Hansson J; Höiom V; Ghiorzo P; Gruis NA; Kanetsky PA; Wendt J; Pjanova D; Puig S; Saiag P; Schadendorf D; Soufir N; Okamoto I; Affleck P; García-Casado Z; Ogbah Z; Ozola A; Queirolo P; Sucker A; Barrett JH; van Doorn R; Bishop DT; Newton-Bishop J
Article: ACTA ORTHOPAEDICA BELGICA. 2012;78(2):246-253

Surgical treatment of skeletal metastases in 31 melanoma patients.

Wedin R; Falkenius J; Weiss RJ; Hansson J
Article: GENES CHROMOSOMES & CANCER. 2011;50(12):1076-1084

Genome-wide linkage analysis of Swedish families to identify putative susceptibility loci for cutaneous malignant melanoma.

Höiom V; Tuominen R; Hansson J
Article: JOURNAL OF TRANSLATIONAL MEDICINE. 2011;9:204

A prospective phase II trial exploring the association between tumor microenvironment biomarkers and clinical activity of ipilimumab in advanced melanoma.

Hamid O; Schmidt H; Nissan A; Ridolfi L; Aamdal S; Hansson J; Guida M; Hyams DM; Gómez H; Bastholt L; Chasalow SD; Berman D
Article: NATURE GENETICS. 2011;43(11):1108-1U98

Genome-wide association study identifies three new melanoma susceptibility loci.

Barrett JH; Iles MM; Harland M; Taylor JC; Aitken JF; Andresen PA; Akslen LA; Armstrong BK; Avril M-F; Azizi E; Bakker B; Bergman W; Bianchi-Scarrà G; Bressac-de Paillerets B; Calista D; Cannon-Albright LA; Corda E; Cust AE; Dębniak T; Duffy D; Dunning AM; Easton DF; Friedman E; Galan P; Ghiorzo P; Giles GG; Hansson J; Hocevar M; Höiom V; Hopper JL; Ingvar C; Janssen B; Jenkins MA; Jönsson G; Kefford RF; Landi G; Landi MT; Lang J; Lubiński J; Mackie R; Malvehy J; Martin NG; Molven A; Montgomery GW; van Nieuwpoort FA; Novakovic S; Olsson H; Pastorino L; Puig S; Puig-Butille JA; Randerson-Moor J; Snowden H; Tuominen R; Van Belle P; van der Stoep N; Whiteman DC; Zelenika D; Han J; Fang S; Lee JE; Wei Q; Lathrop GM; Gillanders EM; Brown KM; Goldstein AM; Kanetsky PA; Mann GJ; Macgregor S; Elder DE; Amos CI; Hayward NK; Gruis NA; Demenais F; Bishop JAN; Bishop DT; GenoMEL Consortium
Article: NATURE GENETICS. 2011;43(11):1114-U104

Genome-wide association study identifies a new melanoma susceptibility locus at 1q21.3.

Macgregor S; Montgomery GW; Liu JZ; Zhao ZZ; Henders AK; Stark M; Schmid H; Holland EA; Duffy DL; Zhang M; Painter JN; Nyholt DR; Maskiell JA; Jetann J; Ferguson M; Cust AE; Jenkins MA; Whiteman DC; Olsson H; Puig S; Bianchi-Scarrà G; Hansson J; Demenais F; Landi MT; Dębniak T; Mackie R; Azizi E; Bressac-de Paillerets B; Goldstein AM; Kanetsky PA; Gruis NA; Elder DE; Newton-Bishop JA; Bishop DT; Iles MM; Helsing P; Amos CI; Wei Q; Wang L-E; Lee JE; Qureshi AA; Kefford RF; Giles GG; Armstrong BK; Aitken JF; Han J; Hopper JL; Trent JM; Brown KM; Martin NG; Mann GJ; Hayward NK
Article: CLINICAL CANCER RESEARCH. 2011;17(12):3933-3942

KIT pathway alterations in mucosal melanomas of the vulva and other sites.

Omholt K; Grafström E; Kanter-Lewensohn L; Hansson J; Ragnarsson-Olding BK
Article: LAKARTIDNINGEN. 2011;108(20):1092-1093

[Paradigmatic shift in oncology: individualized melanoma treatment].

Hansson J; Djureen-Mårtenson E; Edvinsson F; Falkenius J; Friesland S; Masucci G; Månsson-Brahme E; Ragnarsson-Olding B; Sjödin H; Wolodarski M; Frohm-Nilsson M; Lapins J
Article: EXPERIMENTAL CELL RESEARCH. 2011;317(8):1119-1133

Melanoma cells produce multiple laminin isoforms and strongly migrate on α5 laminin(s) via several integrin receptors.

Oikawa Y; Hansson J; Sasaki T; Rousselle P; Domogatskaya A; Rodin S; Tryggvason K; Patarroyo M
Article: LANCET ONCOLOGY. 2011;12(2):144-152

Two different durations of adjuvant therapy with intermediate-dose interferon alfa-2b in patients with high-risk melanoma (Nordic IFN trial): a randomised phase 3 trial.

Hansson J; Aamdal S; Bastholt L; Brandberg Y; Hernberg M; Nilsson B; Stierner U; von der Maase H; Nordic Melanoma Cooperative Group
Article: JOURNAL OF INVESTIGATIVE DERMATOLOGY. 2010;130(12):2809-2817

High frequency of p16(INK4A) promoter methylation in NRAS-mutated cutaneous melanoma.

Jonsson A; Tuominen R; Grafström E; Hansson J; Egyhazi S
Article: JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE. 2010;102(20):1568-1583

Association of MC1R variants and host phenotypes with melanoma risk in CDKN2A mutation carriers: a GenoMEL study.

Demenais F; Mohamdi H; Chaudru V; Goldstein AM; Newton Bishop JA; Bishop DT; Kanetsky PA; Hayward NK; Gillanders E; Elder DE; Avril MF; Azizi E; van Belle P; Bergman W; Bianchi-Scarrà G; Bressac-de Paillerets B; Calista D; Carrera C; Hansson J; Harland M; Hogg D; Höiom V; Holland EA; Ingvar C; Landi MT; Lang JM; Mackie RM; Mann GJ; Ming ME; Njauw CJ; Olsson H; Palmer J; Pastorino L; Puig S; Randerson-Moor J; Stark M; Tsao H; Tucker MA; van der Velden P; Yang XR; Gruis N; Melanoma Genetics Consortium
Article: JOURNAL OF INVESTIGATIVE DERMATOLOGY. 2010;130(8):2062-2070

MicroRNA expression profiles associated with mutational status and survival in malignant melanoma.

Caramuta S; Egyházi S; Rodolfo M; Witten D; Hansson J; Larsson C; Lui W-O
Article: AMERICAN JOURNAL OF HUMAN GENETICS. 2010;87(1):6-16

IRF4 variants have age-specific effects on nevus count and predispose to melanoma.

Duffy DL; Iles MM; Glass D; Zhu G; Barrett JH; Höiom V; Zhao ZZ; Sturm RA; Soranzo N; Hammond C; Kvaskoff M; Whiteman DC; Mangino M; Hansson J; Newton-Bishop JA; GenoMEL; Bataille V; Hayward NK; Martin NG; Bishop DT; Spector TD; Montgomery GW
Article: CANCER RESEARCH. 2010;70(11):4335-4345

Immature immunosuppressive CD14+HLA-DR-/low cells in melanoma patients are Stat3hi and overexpress CD80, CD83, and DC-sign.

Poschke I; Mougiakakos D; Hansson J; Masucci GV; Kiessling R
Article: SCANDINAVIAN JOURNAL OF PLASTIC AND RECONSTRUCTIVE SURGERY AND HAND SURGERY. 2010;44(3):146-155

Surgical resection margins do not influence health related quality of life or emotional distress in patients with cutaneous melanoma: results of a prospective randomised trial.

Bergenmar M; Månsson-Brahme E; Hansson J; Brandberg Y
Article: CELL BIOLOGY AND TRANSLATIONAL MEDICINE, VOL 14: STEM CELLS IN LINEAGE SPECIFIC DIFFERENTIATION AND DISEASE. 2010;685:134-145

Familial cutaneous melanoma.

Hansson J
Article: CANCER IMMUNOLOGY IMMUNOTHERAPY. 2009;58(10):1599-1608

The common Scandinavian human leucocyte antigen ancestral haplotype 62.1 as prognostic factor in patients with advanced malignant melanoma.

Helgadottir H; Andersson E; Villabona L; Kanter L; van der Zanden H; Haasnoot GW; Seliger B; Bergfeldt K; Hansson J; Ragnarsson-Olding B; Kiessling R; Masucci GV
Article: NATURE GENETICS. 2009;41(8):920-U85

Genome-wide association study identifies three loci associated with melanoma risk.

Bishop DT; Demenais F; Iles MM; Harland M; Taylor JC; Corda E; Randerson-Moor J; Aitken JF; Avril M-F; Azizi E; Bakker B; Bianchi-Scarrà G; Bressac-de Paillerets B; Calista D; Cannon-Albright LA; Chin-A-Woeng T; Debniak T; Galore-Haskel G; Ghiorzo P; Gut I; Hansson J; Hocevar M; Höiom V; Hopper JL; Ingvar C; Kanetsky PA; Kefford RF; Landi MT; Lang J; Lubiński J; Mackie R; Malvehy J; Mann GJ; Martin NG; Montgomery GW; van Nieuwpoort FA; Novakovic S; Olsson H; Puig S; Weiss M; van Workum W; Zelenika D; Brown KM; Goldstein AM; Gillanders EM; Boland A; Galan P; Elder DE; Gruis NA; Hayward NK; Lathrop GM; Barrett JH; Bishop JAN
Article: NATURE GENETICS. 2009;41(8):909-914

New common variants affecting susceptibility to basal cell carcinoma.

Stacey SN; Sulem P; Masson G; Gudjonsson SA; Thorleifsson G; Jakobsdottir M; Sigurdsson A; Gudbjartsson DF; Sigurgeirsson B; Benediktsdottir KR; Thorisdottir K; Ragnarsson R; Scherer D; Hemminki K; Rudnai P; Gurzau E; Koppova K; Botella-Estrada R; Soriano V; Juberias P; Saez B; Gilaberte Y; Fuentelsaz V; Corredera C; Grasa M; Höiom V; Lindblom A; Bonenkamp JJ; van Rossum MM; Aben KKH; de Vries E; Santinami M; Di Mauro MG; Maurichi A; Wendt J; Hochleitner P; Pehamberger H; Gudmundsson J; Magnusdottir DN; Gretarsdottir S; Holm H; Steinthorsdottir V; Frigge ML; Blondal T; Saemundsdottir J; Bjarnason H; Kristjansson K; Bjornsdottir G; Okamoto I; Rivoltini L; Rodolfo M; Kiemeney LA; Hansson J; Nagore E; Mayordomo JI; Kumar R; Karagas MR; Nelson HH; Gulcher JR; Rafnar T; Thorsteinsdottir U; Olafsson JH; Kong A; Stefansson K
Article: CANCER IMMUNOLOGY IMMUNOTHERAPY. 2009;58(7):1085-1094

Prognostic significance of tumor iNOS and COX-2 in stage III malignant cutaneous melanoma.

Johansson CC; Egyházi S; Masucci G; Harlin H; Mougiakakos D; Poschke I; Nilsson B; Garberg L; Tuominen R; Linden D; Stolt MF; Hansson J; Kiessling R
Article: JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE. 2009;101(12):869-877

Autoimmune antibodies and recurrence-free interval in melanoma patients treated with adjuvant interferon.

Bouwhuis MG; Suciu S; Collette S; Aamdal S; Kruit WH; Bastholt L; Stierner U; Salès F; Patel P; Punt CJA; Hernberg M; Spatz A; ten Hagen TLM; Hansson J; Eggermont AMM; EORTC Melanoma Group and the Nordic Melanoma Group
Article: CANCER RESEARCH. 2009;69(9):3746-3754

Species-specific in vivo engraftment of the human BL melanoma cell line results in an invasive dedifferentiated phenotype not present in xenografts.

Cedervall J; Jamil S; Prasmickaite L; Cheng Y; Eskandarpour M; Hansson J; Maelandsmo GM; Ringborg U; Gulyas M; Zhen HS; Kanter L; Ahrlund-Richter L
Article: PIGMENT CELL & MELANOMA RESEARCH. 2009;22(2):196-204

MC1R variation and melanoma risk in the Swedish population in relation to clinical and pathological parameters.

Höiom V; Tuominen R; Käller M; Lindén D; Ahmadian A; Månsson-Brahme E; Egyhazi S; Sjöberg K; Lundeberg J; Hansson J
Article: EUROPEAN JOURNAL OF ONCOLOGY NURSING. 2009;13(2):74-80

Family members' perceptions of genetic testing for malignant melanoma--a prospective interview study.

Bergenmar M; Hansson J; Brandberg Y
Article: NATURE GENETICS. 2009;41(2):221-227

Sequence variants at the TERT-CLPTM1L locus associate with many cancer types.

Rafnar T; Sulem P; Stacey SN; Geller F; Gudmundsson J; Sigurdsson A; Jakobsdottir M; Helgadottir H; Thorlacius S; Aben KKH; Blöndal T; Thorgeirsson TE; Thorleifsson G; Kristjansson K; Thorisdottir K; Ragnarsson R; Sigurgeirsson B; Skuladottir H; Gudbjartsson T; Isaksson HJ; Einarsson GV; Benediktsdottir KR; Agnarsson BA; Olafsson K; Salvarsdottir A; Bjarnason H; Asgeirsdottir M; Kristinsson KT; Matthiasdottir S; Sveinsdottir SG; Polidoro S; Höiom V; Botella-Estrada R; Hemminki K; Rudnai P; Bishop DT; Campagna M; Kellen E; Zeegers MP; de Verdier P; Ferrer A; Isla D; Vidal MJ; Andres R; Saez B; Juberias P; Banzo J; Navarrete S; Tres A; Kan D; Lindblom A; Gurzau E; Koppova K; de Vegt F; Schalken JA; van der Heijden HFM; Smit HJ; Termeer RA; Oosterwijk E; van Hooij O; Nagore E; Porru S; Steineck G; Hansson J; Buntinx F; Catalona WJ; Matullo G; Vineis P; Kiltie AE; Mayordomo JI; Kumar R; Kiemeney LA; Frigge ML; Jonsson T; Saemundsson H; Barkardottir RB; Jonsson E; Jonsson S; Olafsson JH; Gulcher JR; Masson G; Gudbjartsson DF; Kong A; Thorsteinsdottir U; Stefansson K
Article: INTERNATIONAL JOURNAL OF CANCER. 2009;124(1):16-26

Oncogenic NRAS has multiple effects on the malignant phenotype of human melanoma cells cultured in vitro.

Eskandarpour M; Huang F; Reeves KA; Clark E; Hansson J
Article: JOURNAL OF INVESTIGATIVE DERMATOLOGY. 2008;128(11):2696-2704

Lack of cytoplasmic ERK activation is an independent adverse prognostic factor in primary cutaneous melanoma.

Jovanovic B; Kröckel D; Linden D; Nilsson B; Egyhazi S; Hansson J
Article: MOLECULAR CANCER THERAPEUTICS. 2008;7(9):2876-2883

Increased cyclin D1 expression can mediate BRAF inhibitor resistance in BRAF V600E-mutated melanomas.

Smalley KSM; Lioni M; Dalla Palma M; Xiao M; Desai B; Egyhazi S; Hansson J; Wu H; King AJ; Van Belle P; Elder DE; Flaherty KT; Herlyn M; Nathanson KL
Article: NATURE GENETICS. 2008;40(7):886-891

ASIP and TYR pigmentation variants associate with cutaneous melanoma and basal cell carcinoma.

Gudbjartsson DF; Sulem P; Stacey SN; Goldstein AM; Rafnar T; Sigurgeirsson B; Benediktsdottir KR; Thorisdottir K; Ragnarsson R; Sveinsdottir SG; Magnusson V; Lindblom A; Kostulas K; Botella-Estrada R; Soriano V; Juberías P; Grasa M; Saez B; Andres R; Scherer D; Rudnai P; Gurzau E; Koppova K; Kiemeney LA; Jakobsdottir M; Steinberg S; Helgason A; Gretarsdottir S; Tucker MA; Mayordomo JI; Nagore E; Kumar R; Hansson J; Olafsson JH; Gulcher J; Kong A; Thorsteinsdottir U; Stefansson K
Article: NATURE GENETICS. 2008;40(7):838-840

Common sequence variants on 20q11.22 confer melanoma susceptibility.

Brown KM; Macgregor S; Montgomery GW; Craig DW; Zhao ZZ; Iyadurai K; Henders AK; Homer N; Campbell MJ; Stark M; Thomas S; Schmid H; Holland EA; Gillanders EM; Duffy DL; Maskiell JA; Jetann J; Ferguson M; Stephan DA; Cust AE; Whiteman D; Green A; Olsson H; Puig S; Ghiorzo P; Hansson J; Demenais F; Goldstein AM; Gruis NA; Elder DE; Bishop JN; Kefford RF; Giles GG; Armstrong BK; Aitken JF; Hopper JL; Martin NG; Trent JM; Mann GJ; Hayward NK
Article: CANCER RESEARCH. 2007;67(19):9006-9012

FBXW7/hCDC4 is a general tumor suppressor in human cancer.

Akhoondi S; Sun D; von der Lehr N; Apostolidou S; Klotz K; Maljukova A; Cepeda D; Fiegl H; Dafou D; Marth C; Mueller-Holzner E; Corcoran M; Dagnell M; Nejad SZ; Nayer BN; Zali MR; Hansson J; Egyhazi S; Petersson F; Sangfelt P; Nordgren H; Grander D; Reed SI; Widschwendter M; Sangfelt O; Spruck C
Article: JOURNAL OF IMMUNOTHERAPY. 2007;30(7):773-779

The prognostic role of blood lymphocyte subset distribution in patients with resected high-risk primary or regionally metastatic melanoma.

Hernberg M; Mattila PS; Rissanen M; Hansson J; Aamdal S; Bastholt L; von der Maase H; Schmidt H; Stierner U; Tarkkanen J
Article: JOURNAL OF MEDICAL GENETICS. 2007;44(2):99-106

Features associated with germline CDKN2A mutations: a GenoMEL study of melanoma-prone families from three continents.

Goldstein AM; Chan M; Harland M; Hayward NK; Demenais F; Bishop DT; Azizi E; Bergman W; Bianchi-Scarra G; Bruno W; Calista D; Albright LAC; Chaudru V; Chompret A; Cuellar F; Elder DE; Ghiorzo P; Gillanders EM; Gruis NA; Hansson J; Hogg D; Holland EA; Kanetsky PA; Kefford RF; Landi MT; Lang J; Leachman SA; MacKie RM; Magnusson V; Mann GJ; Bishop JN; Palmer JM; Puig S; Puig-Butille JA; Stark M; Tsao H; Tucker MA; Whitaker L; Yakobson E; Lund Melanoma Study Group; Melanoma Genetics Consortium (GenoMEL)
Article: MELANOMA RESEARCH. 2006;16(6):471-478

NRAS and BRAF mutations in melanoma tumours in relation to clinical characteristics: a study based on mutation screening by pyrosequencing.

Edlundh-Rose E; Egyházi S; Omholt K; Månsson-Brahme E; Platz A; Hansson J; Lundeberg J
Article: CANCER RESEARCH. 2006;66(20):9818-9828

High-risk melanoma susceptibility genes and pancreatic cancer, neural system tumors, and uveal melanoma across GenoMEL.

Goldstein AM; Chan M; Harland M; Gillanders EM; Hayward NK; Avril M-F; Azizi E; Bianchi-Scarra G; Bishop DT; Bressac-de Paillerets B; Bruno W; Calista D; Cannon Albright LA; Demenais F; Elder DE; Ghiorzo P; Gruis NA; Hansson J; Hogg D; Holland EA; Kanetsky PA; Kefford RF; Landi MT; Lang J; Leachman SA; Mackie RM; Magnusson V; Mann GJ; Niendorf K; Newton Bishop J; Palmer JM; Puig S; Puig-Butille JA; de Snoo FA; Stark M; Tsao H; Tucker MA; Whitaker L; Yakobson E; Melanoma Genetics Consortium (GenoMEL)
Article: MELANOMA RESEARCH. 2006;16(4):357-363

Alternating chemo-immunotherapy with temozolomide and low-dose interleukin-2 in patients with metastatic melanoma.

Masucci GV; Månsson-Brahme E; Ragnarsson-Olding B; Nilsson B; Wagenius G; Hansson J
Article: MELANOMA RESEARCH. 2006;16(2):197-200

Mutations of PIK3CA are rare in cutaneous melanoma.

Omholt K; Kröckel D; Ringborg U; Hansson J
Article: CLINICAL CHEMISTRY. 2005;51(12):2388-2391

Detection of MC1R polymorphisms with protease-mediated allele-specific extension as an alternative to direct sequencing.

Käller M; Tuominen R; Ahmadian A; Magnusson V; Egyhazi S; Hansson J; Lundeberg J
Article: SKIN RESEARCH AND TECHNOLOGY. 2005;11(4):281-286

Non-invasive and microinvasive electrical impedance spectra of skin cancer - a comparison between two techniques.

Aberg P; Geladi P; Nicander I; Hansson J; Holmgren U; Ollmar S
Article: INTERNATIONAL JOURNAL OF CANCER. 2005;115(1):65-73

Suppression of oncogenic NRAS by RNA interference induces apoptosis of human melanoma cells.

Eskandarpour M; Kiaii S; Zhu C; Castro J; Sakko AJ; Hansson J
Article: CLINICAL CANCER RESEARCH. 2005;11(8):2991-2997

Biallelic deletions in INK4 in cutaneous melanoma are common and associated with decreased survival.

Grafström E; Egyházi S; Ringborg U; Hansson J; Platz A
Article: MELANOMA RESEARCH. 2005;15(2):125-132

Effect of primary site on prognosis in patients with cutaneous malignant melanoma. A study using a new model to analyse anatomical locations.

Gillgren P; Brattström G; Frisell J; Persson J-O; Ringborg U; Hansson J
Article: IEEE TRANSACTIONS ON BIOMEDICAL ENGINEERING. 2004;51(12):2097-2102

Skin cancer identification using multifrequency electrical impedance--a potential screening tool.

Aberg P; Nicander I; Hansson J; Geladi P; Holmgren U; Ollmar S
Article: CANCER. 2004;101(9):2067-2078

Invasive cutaneous malignant melanoma in Sweden, 1990-1999. A prospective, population-based study of survival and prognostic factors.

Lindholm C; Andersson R; Dufmats M; Hansson J; Ingvar C; Möller T; Sjödin H; Stierner U; Wagenius G; Swedish Melanoma Study Group
Article: LARYNGOSCOPE. 2004;114(9):1660-1667

High-dose Cisplatin with amifostine: ototoxicity and pharmacokinetics.

Ekborn A; Hansson J; Ehrsson H; Eksborg S; Wallin I; Wagenius G; Laurell G
Article: MELANOMA RESEARCH. 2004;14(4):251-255

Germline CDKN2A mutations are rare in child and adolescent cutaneous melanoma.

Berg P; Wennberg A-M; Tuominen R; Sander B; Rozell BL; Platz A; Hansson J
Article: CANCER RESEARCH. 2004;64(3):807-811

Induction of melanoma phenotypes in human skin by growth factors and ultraviolet B.

Berking C; Takemoto R; Satyamoorthy K; Shirakawa T; Eskandarpour M; Hansson J; VanBelle PA; Elder DE; Herlyn M
Article: ACTA ONCOLOGICA. 2004;43(2):161-168

Anxiety and depressive symptoms measured by the Hospital Anxiety and Depression Scale as predictors of time to recurrence in localized cutaneous melanoma.

Bergenmar M; Nilsson B; Hansson J; Brandberg Y
Article: HUMAN PATHOLOGY. 2004;35(1):25-33

Expression and localization of mutant p16 proteins in melanocytic lesions from familial melanoma patients.

Ghiorzo P; Villaggio B; Sementa AR; Hansson J; Platz A; Nicoló G; Spina B; Canepa M; Palmer JM; Hayward NK; Bianchi-Scarrà G
Article: CLINICAL CANCER RESEARCH. 2003;9(17):6483-6488

NRAS and BRAF mutations arise early during melanoma pathogenesis and are preserved throughout tumor progression.

Omholt K; Platz A; Kanter L; Ringborg U; Hansson J
Article: BRITISH JOURNAL OF CANCER. 2003;89(8):1517-1523

O6-methylguanine-DNA-methyltransferase expression and gene polymorphisms in relation to chemotherapeutic response in metastatic melanoma.

Ma S; Egyházi S; Ueno T; Lindholm C; Kreklau EL; Stierner U; Ringborg U; Hansson J
Article: JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE. 2003;95(20):1530-1538

A prospective study of pigmentation, sun exposure, and risk of cutaneous malignant melanoma in women.

Veierød MB; Weiderpass E; Thörn M; Hansson J; Lund E; Armstrong B; Adami H-O
Article: AMERICAN JOURNAL OF HUMAN GENETICS. 2003;73(2):301-313

Localization of a novel melanoma susceptibility locus to 1p22.

Gillanders E; Juo S-HH; Holland EA; Jones M; Nancarrow D; Freas-Lutz D; Sood R; Park N; Faruque M; Markey C; Kefford RF; Palmer J; Bergman W; Bishop DT; Tucker MA; Bressac-de Paillerets B; Hansson J; Stark M; Gruis N; Bishop JN; Goldstein AM; Bailey-Wilson JE; Mann GJ; Hayward N; Trent J; Lund Melanoma Study Group; Melanoma Genetics Consortium
Article: JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE. 2003;95(11):790-798

Frequency of UV-inducible NRAS mutations in melanomas of patients with germline CDKN2A mutations.

Eskandarpour M; Hashemi J; Kanter L; Ringborg U; Platz A; Hansson J
Article: MELANOMA RESEARCH. 2003;13(3):279-286

Body site of cutaneous malignant melanoma--a study on patients with hereditary and multiple sporadic tumours.

Gillgren P; Brattström G; Frisell J; Palmgren J; Ringborg U; Hansson J
Article: EUROPEAN JOURNAL OF CANCER. 2003;39(8):1115-1120

Bleomycin, vincristine, lomustine and dacarbazine (BOLD) in combination with recombinant interferon alpha-2b for metastatic uveal melanoma.

Kivelä T; Suciu S; Hansson J; Kruit WHJ; Vuoristo M-S; Kloke O; Gore M; Hahka-Kemppinen M; Parvinen L-M; Kumpulainen E; Humblet Y; Pyrhönen S
Article: JOURNAL OF BIOLOGICAL CHEMISTRY. 2003;278(11):9100-9106

Cisplatin induces endoplasmic reticulum stress and nucleus-independent apoptotic signaling.

Mandic A; Hansson J; Linder S; Shoshan MC
Article: SCANDINAVIAN JOURNAL OF UROLOGY AND NEPHROLOGY. 2003;37(2):106-111

Bladder neoplasms--regions at chromosome 9 with putative tumour suppressor genes.

Wada T; Berggren P; Steineck G; Adolfsson J; Wijkström H; Norming U; Hansson J; Hemminki K; Larsson P
Article: CLINICAL CHEMISTRY. 2002;48(12):2164-2170

Pyrosequencing as an alternative to single-strand conformation polymorphism analysis for detection of N-ras mutations in human melanoma metastases.

Sivertsson A; Platz A; Hansson J; Lundeberg J
Article: CLINICAL CANCER RESEARCH. 2002;8(11):3468-3474

Screening of N-ras codon 61 mutations in paired primary and metastatic cutaneous melanomas: mutations occur early and persist throughout tumor progression.

Omholt K; Karsberg S; Platz A; Kanter L; Ringborg U; Hansson J
Article: HUMAN MUTATION. 2002;20(5):408-409

Novel O6-methylguanine-DNA methyltransferase SNPs: a frequency comparison of patients with familial melanoma and healthy individuals in Sweden.

Egyházi S; Ma S; Smoczynski K; Hansson J; Platz A; Ringborg U
Article: ONCOLOGY REPORTS. 2002;9(5):1015-1019

Immunohistochemical analysis of DNA mismatch repair protein and O6-methylguanine-DNA methyltransferase in melanoma metastases in relation to clinical response to DTIC-based chemotherapy.

Ma S; Egyházi S; Ringborg U; Hansson J
Article: MELANOMA RESEARCH. 2002;12(4):335-342

Analysis of O(6)-methylguanine-DNA methyltransferase in melanoma tumours in patients treated with dacarbazine-based chemotherapy.

Ma S; Egyházi S; Martenhed G; Ringborg U; Hansson J
Article: CANCER LETTERS. 2002;180(2):211-221

A melanoma-predisposing germline CDKN2A mutation with functional significance for both p16 and p14ARF.

Hashemi J; Lindström MS; Asker C; Platz A; Hansson J; Wiman KG
Article: JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE. 2002;94(12):894-903

Geographical variation in the penetrance of CDKN2A mutations for melanoma.

Bishop DT; Demenais F; Goldstein AM; Bergman W; Bishop JN; Bressac-de Paillerets B; Chompret A; Ghiorzo P; Gruis N; Hansson J; Harland M; Hayward N; Holland EA; Mann GJ; Mantelli M; Nancarrow D; Platz A; Tucker MA; Melanoma Genetics Consortium
Article: BRITISH JOURNAL OF DERMATOLOGY. 2002;146(6):1023-1030

A new computerized methodology to analyse tumour site in relation to phenotypic traits and epidemiological characteristics of cutaneous malignant melanoma.

Gillgren P; Brattström G; Djureen Mårtensson E; Frisell J; Palmgren J; Ringborg U; Hansson J
Article: MOLECULAR AND CELLULAR BIOLOGY. 2002;22(9):3003-3013

Calpain-mediated Bid cleavage and calpain-independent Bak modulation: two separate pathways in cisplatin-induced apoptosis.

Mandic A; Viktorsson K; Strandberg L; Heiden T; Hansson J; Linder S; Shoshan MC
Article: CYTOPATHOLOGY. 2002;13(1):11-21

Expression of CD40, CD44, bcl-2 antigens and rate of cell proliferation on fine needle aspirates from metastatic melanoma.

Sviatoha V; Rundgren A; Tani E; Hansson J; Kleina R; Skoog L
Article: EUROPEAN JOURNAL OF CANCER PREVENTION. 2002;11(1):49-55

Detection of nodular and superficial spreading melanoma with tumour thickness < or = 2.0 mm--an interview study.

Bergenmar M; Hansson J; Brandberg Y
Article: INTERNATIONAL JOURNAL OF CANCER. 2001;92(6):839-842

Cytoplasmic and nuclear accumulation of beta-catenin is rarely caused by CTNNB1 exon 3 mutations in cutaneous malignant melanoma.

Omholt K; Platz A; Ringborg U; Hansson J
Article: BJU INTERNATIONAL. 2001;87(9):876-881

The prevalence of loss of heterozygosity in chromosome 3, including FHIT, in bladder cancer, using the fluorescent multiplex polymerase chain reaction.

Wada T; Louhelainen J; Hemminki K; Adolfsson J; Wijkström H; Norming U; Borgström E; Hansson J; Steineck G
Article: BRITISH JOURNAL OF CANCER. 2001;84(11):1505-1511

p53 mutations in urinary bladder cancer.

Berggren P; Steineck G; Adolfsson J; Hansson J; Jansson O; Larsson P; Sandstedt B; Wijkström H; Hemminki K
Article: MOLECULAR AND CELLULAR BIOLOGY. 2001;21(11):3684-3691

Cisplatin induces the proapoptotic conformation of Bak in a deltaMEKK1-dependent manner.

Mandic A; Viktorsson K; Molin M; Akusjärvi G; Eguchi H; Hayashi SI; Toi M; Hansson J; Linder S; Shoshan MC
Article: GENES CHROMOSOMES & CANCER. 2001;31(2):107-116

Haplotype analysis and age estimation of the 113insR CDKN2A founder mutation in Swedish melanoma families.

Hashemi J; Bendahl PO; Sandberg T; Platz A; Linder S; Stierner U; Olsson H; Ingvar C; Hansson J; Borg A
Article: BRITISH JOURNAL OF CANCER. 2001;84(3):329-334

Low interleukin-1alpha messenger RNA levels predict decreased overall survival time of patients with urinary bladder carcinoma.

Seddighzadeh M; Steineck G; Jansson O; Larsson P; Wijkström H; Adolfsson J; Portwood N; Hansson J; Linder S
Article: JOURNAL OF CLINICAL ONCOLOGY. 2001;19(3):824-831

Serum S-100b protein as a prognostic marker in malignant cutaneous melanoma.

Mårtenson ED; Hansson LO; Nilsson B; von Schoultz E; Månsson Brahme E; Ringborg U; Hansson J
Article: MELANOMA RESEARCH. 2001;11(1):11-19

The MEK1 inhibitor PD98059 sensitizes C8161 melanoma cells to cisplatin-induced apoptosis.

Mandic A; Viktorsson K; Heiden T; Hansson J; Shoshan MC
Article: CANCER RESEARCH. 2000;60(24):6864-6867

CDKN2A germ-line mutations in individuals with multiple cutaneous melanomas.

Hashemi J; Platz A; Ueno T; Stierner U; Ringborg U; Hansson J
Article: SEMINARS IN CANCER BIOLOGY. 2000;10(4):319-326

Hereditary cutaneous melanoma.

Platz A; Ringborg U; Hansson J
Article: JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE. 2000;92(9):758A-7759

Re: biologic and biochemical analyses of p16(INK4a) mutations from primary tumors.

Hansson J; Hashemi J; Linder S; Platz A
Article: CLINICAL CANCER RESEARCH. 2000;6(2):610-615

Bladder cancer: allelic deletions at and around the retinoblastoma tumor suppressor gene in relation to stage and grade.

Wada T; Louhelainen J; Hemminki K; Adolfsson J; Wijkström H; Norming U; Borgström E; Hansson J; Sandstedt B; Steineck G
Article: MELANOMA RESEARCH. 1999;9(1):21-30

Melanoma development in relation to non-functional p16/INK4A protein and dysplastic naevus syndrome in Swedish melanoma kindreds.

Hashemi J; Linder S; Platz A; Hansson J
Article: INTERNATIONAL JOURNAL OF CANCER. 1998;78(1):13-15

Screening of germline mutations in the CDK4, CDKN2C and TP53 genes in familial melanoma: a clinic-based population study.

Platz A; Hansson J; Ringborg U
Article: JOURNAL OF INTERFERON AND CYTOKINE RESEARCH. 1998;18(9):691-695

In vivo induction of the interferon-stimulated protein 2'5'-oligoadenylate synthetase in tumor and peripheral blood cells during IFN-alpha treatment of metastatic melanoma.

Grandér D; Sangfelt O; Skoog L; Hansson J
Article: CARCINOGENESIS. 1997;18(10):1889-1895

O6-methylguanine-DNA methyltransferase activity in human buccal mucosal tissue and cell cultures. Complex mixtures related to habitual use of tobacco and betel quid inhibit the activity in vitro.

Liu Y; Egyhazi S; Hansson J; Bhide SV; Kulkarni PS; Grafström RC
Article: LAKARTIDNINGEN. 1997;94(28-29):2543-2544

[Delayed diagnosis of subungual melanoma. Two cases were misjudged as onychomycosis].

Wallberg B; Hansson J
Article: LAKARTIDNINGEN. 1997;94(28-29):2539-2543

[Malignant skin melanoma a difficult clinical diagnosis. The primary management is often insufficient].

Wallberg B; Hansson J
Article: ANTICANCER RESEARCH. 1997;17(4B):3071-3073

Prognostic value of serum analyses of S-100 protein beta in malignant melanoma.

Hansson LO; von Schoultz E; Djureen E; Hansson J; Nilsson B; Ringborg U
Article: ANTICANCER RESEARCH. 1997;17(4A):2347-2352

The Ras farnesylation inhibitor BZA-5B increases the resistance to cisplatin in a human melanoma cell line.

Fokstuen T; Rabo YB; Zhou JN; Karlson J; Platz A; Shoshan MC; Hansson J; Linder S
Article: STEM CELLS AND DEVELOPMENT. 1997;6(3):253-260

Efficient harvest of in vivo IL-2-activated CD3+ lymphocytes for adoptive immunotherapy by selective leukapheresis (lymphocytapheresis).

Masucci G; Svensson A; Hansson M; Hansson J; Nakazawa T; Salazar F; Petersson M; Kiessling R
Article: MEDICAL ONCOLOGY. 1997;14(2):73-81

Systemic therapy of malignant melanoma.

Hansson J
Article: JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE. 1997;89(10):697-702

Screening of germline mutations in the CDKN2A and CDKN2B genes in Swedish families with hereditary cutaneous melanoma.

Platz A; Hansson J; Månsson-Brahme E; Lagerlof B; Linder S; Lundqvist E; Sevigny P; Inganäs M; Ringborg U
Article: EUROPEAN JOURNAL OF CANCER. 1997;33(3):447-452

Role of O6-methylguanine-DNA methyltransferase, glutathione transferase M3-3 and glutathione in resistance to carmustine in a human non-small cell lung cancer cell line.

Egyházi S; Edgren MR; Hansson J; Kröckel D; Mannervik B; Ringborg U
Article: EUROPEAN JOURNAL OF CANCER. 1997;33(1):129-134

Immunohistochemical examination of the expression of O6-methylguanine-DNA methyltransferase in human melanoma metastases.

Egyházi S; Margison GP; Hansson J; Ringborg U
Article: CARCINOGENESIS. 1997;18(1):9-13

Tamoxifen-induced DNA adducts in leucocytes of breast cancer patients.

Hemminki K; Rajaniemi H; Koskinen M; Hansson J
Article: EUROPEAN JOURNAL OF CANCER. 1996;32A(13):2319-2326

Analysis of O6-methylguanine-DNA methyltransferase mRNA in fine needle biopsies from human melanoma metastases by reverse transcription and polymerase chain reaction.

Hansson J; Martenhed G; Egyházi S; Tani E; Platz A
Article: EUROPEAN JOURNAL OF IMMUNOLOGY. 1996;26(6):1308-1313

Hydrogen peroxide secreted by tumor-derived macrophages down-modulates signal-transducing zeta molecules and inhibits tumor-specific T cell-and natural killer cell-mediated cytotoxicity.

Kono K; Salazar-Onfray F; Petersson M; Hansson J; Masucci G; Wasserman K; Nakazawa T; Anderson P; Kiessling R
Article: MELANOMA RESEARCH. 1996;6(2):133-137

Prognostic value of serum analyses of S-100 beta protein in malignant melanoma.

von Schoultz E; Hansson LO; Djureen E; Hansson J; Kärnell R; Nilsson B; Stigbrand T; Ringborg U
Article: INTERNATIONAL JOURNAL OF CANCER. 1996;65(6):821-826

Different mechanisms are responsible for c-jun mRNA induction by cisplatin and ultraviolet light.

Rabo YB; Shoshan MC; Linder S; Hansson J
Article: ACTA ONCOLOGICA. 1996;35(6):683-690

Increased cisplatin sensitivity of human fibroblasts from a subject with inherent glutathione deficiency.

Hansson J; Edgren MR; Egyházi S; Hao XY; Mannervik B; Ringborg U
Article: ANTI-CANCER DRUGS. 1995;6(5):657-668

Apoptosis and c-jun induction by cisplatin in a human melanoma cell line and a drug-resistant daughter cell line.

Zhao R; Rabo YB; Egyházi S; Andersson A; Edgren MR; Linder S; Hansson J
Article: ACTA ONCOLOGICA. 1995;34(1):35-41

The expression of glutathione transferase isoenzymes in human malignant lymphoma biopsies.

Berhane K; Hao XY; Christensson B; Hansson J; Ringborg U; Mannervik B
Visa fler

Alla övriga publikationer

Editorial comment: JOURNAL OF INVESTIGATIVE DERMATOLOGY. 2022;142(3 Pt A):736-740.e6

Coexpression of MTH1 and PMS2 Is Associated with Advanced Disease and Disease Progression after Therapy in Melanoma.

Das I; Tuominen R; Helleday T; Hansson J; Warpman Berglund U; Egyházi Brage S
Editorial comment: ACTA DERMATO-VENEREOLOGICA. 2020;100(18):adv00334-0

Bullous Pemphigoid-like Eruption Triggered by Targeted Therapy for Metastatic Melanoma.

Eriksson H; Hansson J; Krynitz B; Masucci G; Girnita A; Lapins J; Huen AO; Tawbi HA; Davies MA; Tetzlaff MT; Curry JL
Corrigendum: ANNALS OF ONCOLOGY. 2019;30(11):1848

Dabrafenib plus trametinib versus dabrafenib monotherapy in patients with metastatic BRAF V600E/K-mutant melanoma: long-term survival and safety analysis of a phase 3 study.

Long GV; Flaherty KT; Stroyakovskiy D; Gogas H; Levchenko E; de Braud F; Larkin J; Garbe C; Jouary T; Hauschild A; Chiarion-Sileni V; Lebbe C; Mandalá M; Millward M; Arance A; Bondarenko I; Haanen JBAG; Hansson J; Utikal J; Ferraresi V; Mohr P; Probachai V; Schadendorf D; Nathan P; Robert C; Ribas A; Davies MA; Lane SR; Legos JJ; Mookerjee B; Grob J-J
Corrigendum: NATURE COMMUNICATIONS. 2019;10(1):299

Publisher Correction: Novel pleiotropic risk loci for melanoma and nevus density implicate multiple biological pathways.

Duffy DL; Zhu G; Li X; Sanna M; Iles MM; Jacobs LC; Evans DM; Yazar S; Beesley J; Law MH; Kraft P; Visconti A; Taylor JC; Liu F; Wright MJ; Henders AK; Bowdler L; Glass D; Ikram MA; Uitterlinden AG; Madden PA; Heath AC; Nelson EC; Green AC; Chanock S; Barrett JH; Brown MA; Hayward NK; MacGregor S; Sturm RA; Hewitt AW; Melanoma GWAS Consortium; Kayser M; Hunter DJ; Newton Bishop JA; Spector TD; Montgomery GW; Mackey DA; Smith GD; Nijsten TE; Bishop DT; Bataille V; Falchi M; Han J; Martin NG
Letter: EUROPEAN JOURNAL OF CANCER. 2018;91:168-170

Eighth American Joint Committee on Cancer (AJCC) melanoma classification: Let us reconsider stage III.

Grob JJ; Schadendorf D; Lorigan P; Ascierto P; Larkin J; Nathan P; Robert C; Hauschild A; Weber J; Daud A; Hamid O; Dummer R; Hansson J; Hoeller C; Schachter J; Van Akkooi ACJ; Garbe C
Letter: ANNALS OF ONCOLOGY. 2017;28(7):1672-1673

Lethal aplastic anemia caused by dual immune checkpoint blockade in metastatic melanoma.

Helgadottir H; Kis L; Ljungman P; Larkin J; Kefford R; Ascierto PA; Hansson J; Masucci G
Review: JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY. 2017;31(4):603-615

Surgical outcomes in patients with cutaneous malignant melanoma in Europe - a systematic literature review.

Costa Svedman F; Spanopoulos D; Taylor A; Amelio J; Hansson J
Letter: JOURNAL OF INVESTIGATIVE DERMATOLOGY. 2016;136(5):1066-1069

Phenotypic and Histopathological Tumor Characteristics According to CDKN2A Mutation Status among Affected Members of Melanoma Families.

Taylor NJ; Handorf EA; Mitra N; Avril M-F; Azizi E; Bergman W; Bianchi-Scarrà G; Bishop DT; Bressac-de Paillerets B; Calista D; Cannon-Albright LA; Cuellar F; Cust AE; Demenais F; Elder DE; Friedman E; Gerdes A-M; Ghiorzo P; Goldstein AM; Grazziotin TC; Hansson J; Hayward NK; Hocevar M; Höiom V; Holland EA; Ingvar C; Landi MT; Landman G; Larre-Borges A; Leachman SA; Mann GJ; Nagore E; Olsson H; Palmer J; Perić B; Pjanova D; Puig S; Schmid H; van der Stoep N; Tucker MA; Wadt KAW; Whitaker L; Yang XR; Newton Bishop JA; Gruis NA; Kanetsky PA; GenoMEL Consortium
Review: CLINICAL EPIDEMIOLOGY. 2016;8:109-122

Stage-specific survival and recurrence in patients with cutaneous malignant melanoma in Europe - a systematic review of the literature.

Svedman FC; Pillas D; Taylor A; Kaur M; Linder R; Hansson J
Corrigendum: TRIALS. 2015;16:334

Erratum to: Isolated hepatic perfusion as a treatment for uveal melanoma liver metastases (the SCANDIUM trial): study protocol for a randomized controlled trial.

Olofsson Bagge R; Ny L; All-Ericsson C; Sternby Eilard M; Rizell M; Cahlin C; Stierner U; Lönn U; Hansson J; Ljuslinder I; Lundgren L; Ullenhag G; Kiilgaard JF; Nilsson J; Lindnér P
Letter: JOURNAL OF INVESTIGATIVE DERMATOLOGY. 2014;134(12):3000-3003

Primary melanoma tumors from CDKN2A mutation carriers do not belong to a distinct molecular subclass.

Staaf J; Harbst K; Lauss M; Ringnér M; Måsbäck A; Howlin J; Jirström K; Harland M; Zebary A; Palmer JM; Ingvar C; Olsson H; Newton-Bishop J; Hansson J; Hayward N; Gruis N; Jönsson G
Review: CANCER IMMUNOLOGY IMMUNOTHERAPY. 2014;63(9):977-983

Myeloid-derived suppressor cells and their role in CTLA-4 blockade therapy.

Pico de Coaña Y; Masucci G; Hansson J; Kiessling R
Letter: JOURNAL OF INVESTIGATIVE DERMATOLOGY. 2014;134(1):287-290

Somatic BRAF and NRAS mutations in familial melanomas with known germline CDKN2A status: a GenoMEL study.

Zebary A; Omholt K; van Doorn R; Ghiorzo P; Harbst K; Hertzman Johansson C; Höiom V; Jönsson G; Pjanova D; Puig S; Scarra GB; Harland M; Olsson H; Egyhazi Brage S; Palmer J; Kanter-Lewensohn L; Vassilaki I; Hayward NK; Newton-Bishop J; Gruis NA; Hansson J; Melanoma Genetics Consortium (GenoMEL)
Corrigendum: CANCER IMMUNOLOGY RESEARCH. 2013;1(6):438

Ipilimumab Treatment Results in an Early Decrease in the Frequency of Circulating Granulocytic Myeloid Derived Suppressor Cells as well as Their Arginase1 Production (vol 1, pg 158, 2013)

de Coana YP; Poschke I; Gentilcore G; Mao Y; Nystrom M; Hansson J; Masucci GV; Kiessling R
Review: LAKARTIDNINGEN. 2013;110(17-18):886-888

[Hedgehog inhibitors. New promising treatment of advanced basal cell carcinoma].

Wolodarski M; Lapins J; Hansson J
Review: LAKARTIDNINGEN. 2013;110(8):410-412

[Synchronous multiple primary melanoma are often missed. Increased attention to the patient's entire skin is required for early diagnosis].

Lapins J; Emtestam L; Hedblad M-A; Girnita A; Lindelöf B; Ljung A; Hansson J
Review: CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY. 2013;85(2):149-161

Adjuvant interferon alfa in malignant melanoma: an interdisciplinary and multinational expert review.

Ascierto PA; Gogas HJ; Grob JJ; Algarra SM; Mohr P; Hansson J; Hauschild A
Letter: JOURNAL OF INVESTIGATIVE DERMATOLOGY. 2010;130(2):618-620

Coexisting NRAS and BRAF mutations in primary familial melanomas with specific CDKN2A germline alterations.

Jovanovic B; Egyhazi S; Eskandarpour M; Ghiorzo P; Palmer JM; Bianchi Scarrà G; Hayward NK; Hansson J
Meeting abstract: EUROPEAN JOURNAL OF CANCER, SUPPLEMENT. 2009;7(2):577

Identification of tumor biopsy markers as potential predictors of ipilimumab clinical activity in patients with advanced melanoma

Schmidt H; Hamid O; Nissan A; Guida M; Aamdal S; Hansson J; Ridolfi R; Berman D; Chasalow SD
Review: SURGICAL CLINICS OF NORTH AMERICA. 2008;88(4):897-viii

Familial melanoma.

Hansson J
Other: JOURNAL OF INVESTIGATIVE DERMATOLOGY. 2008;128(8):1875-1877

Meeting report of the conference on UV-Radiation-Induced Disease--Roles of UVA and UVB.

Emeny J; Hansson J; Toftgård R; Segerbäck D
Corrigendum: NATURE GENETICS. 2008;40(8):1029

ASIP and TYR pigmentation variants associate with cutaneous melanoma and basal cell carcinoma (vol 40, pg 886, 2008)

Gudbjartsson DF; Sulem P; Stacey SN; Goldstein AM; Rafnar T; Sigurgeirsson B; Benediktsdottir KR; Thorisdottir K; Ragnarsson R; Sveinsdottir SG; Magnusson V; Lindblom A; Kostulas K; Botella-Estrada R; Soriano V; Juberias P; Grasa M; Saez B; Andres R; Scherer D; Rudnai P; Gurzau E; Koppova K; Kiemeney LA; Jakobsdottir M; Steinberg S; Helgason A; Gretarsdottir S; Tucker MA; Mayordomo JI; Nagore E; Kumar R; Hansson J; Olafsson JH; Gulcher J; Kong A; Thorsteinsdottir U; Stefansson K
Review: MOLECULAR ONCOLOGY. 2008;1(4):395-405

Human cutaneous melanoma; a review of NRAS and BRAF mutation frequencies in relation to histogenetic subclass and body site.

Platz A; Egyhazi S; Ringborg U; Hansson J
Corrigendum: CANCER RESEARCH. 2008;68(4):1245

The FBXW7 gene is mutated in a variety of human tumors (vol 67, pg 9006, 2007)

Akhoondi S; Sun D; von der Lehr N; Apostolidou S; Klotz K; Maljukova A; Capeda D; Fiegl H; Dafou D; Marth C; Mueller-Holzner E; Corcoran M; Dagnell M; Nejad SZ; Nayer BN; Zali MR; Hansson J; Egyhazi S; Petersson F; Sangfelt P; Nordgren H; Grander D; Reed SI; Widschwendter M; Sangfelt O; Spruck C
Letter: MELANOMA RESEARCH. 2007;17(6):410-412

No evidence of RALGDS mutations in cutaneous melanoma.

Omholt K; Hansson J
Meeting abstract: EUROPEAN JOURNAL OF CANCER, SUPPLEMENT. 2007;5(4):40

Managing melanoma families in the clinic

Hansson J
Meeting abstract: EUROPEAN JOURNAL OF CANCER, SUPPLEMENT. 2007;5(6):4

Results of the Nordic randomised adjuvant trial of intermediate-dose interferon alfa-2b in high-risk melanoma

Hansson J; Aamdal S; Bastholt L; Hernberg M; Nilsson B; Stierner U; von der Maase H
Published paper: JOURNAL OF CLINICAL ONCOLOGY. 2007;25(19):2819-2824

Monitoring of kindreds with hereditary predisposition for cutaneous melanoma and dysplastic nevus syndrome: results of a Swedish preventive program.

Hansson J; Bergenmar M; Hofer P-A; Lundell G; Månsson-Brahme E; Ringborg U; Synnerstad I; Bratel AT; Wennberg A-M; Rosdahl I
Editorial comment: ACTA ONCOLOGICA. 2006;45(4):369-372

Adjuvant therapy of cutaneous melanoma -- current status.

Hansson J
Editorial comment: ACTA ONCOLOGICA. 2005;44(7):773-777

Loco-regional control of cutaneous metastases of malignant melanoma by treatment with miltefosine (Miltex).

Ragnarsson-Olding B; Djureen-Mårtensson E; Månsson-Brahme E; Hansson J
Editorial comment: LANCET ONCOLOGY. 2002;3(11):653-654

Genetic testing for melanoma.

Kefford R; Bishop JN; Tucker M; Bressac-de Paillerets B; Bianchi-Scarrá G; Bergman W; Goldstein A; Puig S; Mackie R; Elder D; Hansson J; Hayward N; Hogg D; Olsson H; Melanoma Genetics Consortium
Letter: JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE. 2000;92(9):758-760

Re: biologic and biochemical analyses of p16(INK4a) mutations from primary tumors.

Hansson J; Hashemi J; Linder S; Platz A
Meeting abstract: EUROPEAN JOURNAL OF CANCER. 1999;35:S369

CDKN2A germline mutations in Swedish kindreds with hereditary cutaneous melanomas

Hansson J; Platz A; Hashemi J; Stierner U; Ringborg U
Editorial comment: ACTA ONCOLOGICA. 1998;37(7-8):627-628

Why some tumors fail to respond to chemotherapy. Comments on a new model of drug sensitivity and resistance.

Hansson J
Published paper: DRUGS OF TODAY. 1996;32:51-59

Modulating nitrosourea response in tumors and normal tissue: Application to fotemustine

Margison GP; Rafferty JA; Elder RH; Kelly J; Watson AJ; Willington MA; Lee SM; Hickson I; Fairbairn LJ; Dexter TM; Jelinek J; Stocking C; Baum C; Ostertag W; Eghyazi S; Hansson J; Ringborg U; Donnelly D; McMurry TBH; McCormick J; McElhinney RS
Other: BRITISH JOURNAL OF CANCER. 1995;71(1):37-39

O6-methylguanine-DNA methyltransferase activities in biopsies of human melanoma tumours.

Egyházi S; Hansson J; Ringborg U
Visa fler

Artiklar

Alla övriga publikationer

Anställningar

Examina och utbildning

Nyheter från KI

Kalenderhändelser från KI